TRP_1170x120_12-19-19

mylan

Mylan and Biocon Biologics announce launch of Semglee for diabetes care

Mylan and Biocon Biologics announce launch of Semglee for diabetes care

 PITTSBURGH—  Mylan N.V.  and Biocon Biologics India Ltd., a subsidiary of Biocon Ltd., announced on Monday the U.S. launch of Semglee (insulin glargine injection) in vial and pre-filled pen presentations, approved to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes. It is not

Viatris reveals branding to reflect new company’s transformative strategy

Viatris reveals branding to reflect new company’s transformative strategy

HERTFORDSHIRE, England— Mylan and Upjohn, a division of Pfizer, unveiled on Thursday the logo and branding for Viatris, the new company that will be formed by combining Mylan and Upjohn.  Viatris will benefit from Mylan and Upjohn’s trusted global offerings and legacy of meeting patient needs around the world. The new logo and branding is

Mylan shareholders approve proposed combination with Upjohn

Mylan shareholders approve proposed combination with Upjohn

HERTFORDSHIRE, England  – Mylan announced that its shareholders overwhelmingly voted to approve the proposed transaction combining Mylan and Upjohn, a division of Pfizer, at the company’s extraordinary general meeting of shareholders. Approximately 99.6% of votes cast were voted in favor of the combination. Mylan executive chairman and future Viatris executive chairman Robert Coury said: “The

Mylan, Pfizer announce Viatris as the new company name 

Mylan, Pfizer announce Viatris as the new company name 

NEW YORK — Mylan and Pfizer  announced earlier this week that the name of the new company to be formed by the planned combination of Mylan and Upjohn, a division of Pfizer, will be Viatris (pronounced ‘viǝ-trīs). Deriving its name from Latin, Viatris embodies the new company’s goal of providing a path—“VIA”—to three—“TRIS”—core goals: expanding

Pfizer combines its off-patent drug business with Mylan

Pfizer combines its off-patent drug business with Mylan

NEW YORK— Pfizer and Mylan announced Monday a definitive agreement to combine Mylan with Upjohn, Pfizer’s off-patent branded and generic established medicines business, creating a new global pharmaceutical company. Under the terms of the agreement, which is structured as an all-stock, Reverse Morris Trust transaction, each Mylan share would be converted into one share of

Lupin and Mylan team up to commercialize Enbrel

Lupin and Mylan team up to commercialize Enbrel

MUMBAI, India and HERTFORDSHIRE, England and PITTSBURGH — Pharma major Lupin and Mylan announced that the two companies will partner to commercialize a biosimilar to Enbrel (etanercept). Through the partnership agreement, Mylan will commercialize Lupin’s proposed etanercept biosimilar in Europe, Australia, New Zealand, Latin America, Africa and most markets throughout Asia. Enbrel is a TNF-inhibitor indicated to

Americares honors Mylan with Power of Partnership Award

Americares honors Mylan with Power of Partnership Award

STAMFORD, Conn. – Americares, in partnership with the Healthcare Distribution Alliance (HDA), has presented its annual Power of Partnership Award to Mylan, in recognition of its outstanding commitment to increasing access to health care around the world. Mylan is among Americares most dedicated and longstanding supporters, providing pharmaceutical products for the organization’s health programs for people affected

Mylan to introduce new Symfi HIV treatment

Mylan to introduce new Symfi HIV treatment

HERTFORDSHIRE, England and PITTSBURGH — Global pharmaceutical company Mylan N.V. recently announced that it will introduce in the U.S. a third cost-saving HIV combination. The U.S. Food and Drug Administration (FDA) approved Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate) 600 mg/300 mg/300 mg tablets, a once-daily, single-tablet regimen (STR), indicated as a complete regimen for the treatment

Teva, Greenstone roll out Viagra generics in U.S.

Teva, Greenstone roll out Viagra generics in U.S.

NEW YORK — The first generic versions of Viagra, Pfizer Inc.’s blockbuster drug for erectile dysfunction, were launched this week in the United States by Teva Pharmaceutical Industries Ltd. and Greenstone LLC. Israel-based Teva said it’s offering sildenafil citrate tablets in dosages of 25 mg, 50 mg and 100 mg. Greenstone, a Peapack, N.J.-based Pfizer subsidiary,

Mylan gains FDA approval for Herceptin biosimilar

Mylan gains FDA approval for Herceptin biosimilar

PITTSBURGH and BENGALURU, India — Mylan N.V. has received Food and Drug Administration approval for Ogivri (trastuzumab-dkst), a biosimilar oncology drug co-developed with Biocon Ltd. Mylan said Friday that Ogivri is a biosimilar of Herceptin (trastuzumab) from Genentech, indicated for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma).

Mylan, DOJ finalize settlement on EpiPen

Mylan, DOJ finalize settlement on EpiPen

PITTSBURGH — Mylan Inc. and Mylan Specialty L.P. have entered an agreement with the U.S. Department of Justice finalizing the $465 million Medicaid drug rebate settlement last fall. Mylan said late Thursday that the settlement, announced Oct. 7, resolves claims over the classification of the EpiPen and EpiPen Jr epinephrine auto-injectors in the Medicaid Drug

Kmart Pharmacy serves up low-cost EpiPen generic

Kmart Pharmacy serves up low-cost EpiPen generic

HOFFMAN ESTATES, Ill. — Kmart Pharmacy is tackling the cost issue with epinephrine auto-injectors for anaphylaxis by knocking down the price of a generic version. Kmart said Tuesday that in response to the sharp hikes in price of epinephrine auto-injector pens, it has lowered the cost of the generic version of Adrenaclick to as low

Mylan grows in OTCs with Cold-EEZE acquisition

Mylan grows in OTCs with Cold-EEZE acquisition

PITTSBURGH — Furthering its expansion in the consumer health care arena, Mylan has closed its acquisition of the Cold-EEZE over-the-counter cold remedy line from ProPhase Labs Inc. The transaction, announced in January, gives Mylan all global rights and assets relating to the Cold-EEZE brand, including all U.S. businesses and U.S. and international trademarks. Cold-EEZE’s broad

Mylan releases Aromasin generic in U.S.

Mylan releases Aromasin generic in U.S.

PITTSBURGH — Mylan N.V. has launched exemestane tablets 25 mg, a breast cancer medication, in the United States. Mylan said its exemestane product is a generic version of Aromasin tablets from Pfizer Inc. Exemestane is indicated for the treatment of certain types of breast cancer in women after menopause. The medication works by reducing estrogen

1 2 3 4